Hologic announced its acquisition of MagVenture, the Danish manufacturer of TMS and theta burst devices used in over 40 countries, for $1.2 billion in cash and stock. The deal, expected to close in Q3, is the largest M&A event in the TMS device sector and consolidates significant market share alongside U.S. competitors Neuronetics and BrainsWay.
MagVenture's MagPro line is widely used in academic medical centers and was the device used in several pivotal Stanford SAINT studies. The company's strength in research-grade devices complements Hologic's existing women's health and surgical portfolios but represents the company's first move into psychiatric neuromodulation.
Industry analysts expect the deal to accelerate U.S. clinic distribution of MagVenture devices, which historically had a smaller domestic footprint than Neuronetics' NeuroStar. Pricing pressure on theta burst hardware is expected as a result.
Antitrust review is anticipated but unlikely to block the deal given that MagVenture's U.S. market share remains under 15%. The Clinical TMS Society released a statement welcoming the increased investment in the field while noting that consolidation in any medical device market warrants ongoing monitoring of pricing for community clinics.
Source
Reporting based on coverage from MedTech Dive. This article is editorial summary intended for general information; it is not medical advice.